Department of Urology, Feinberg School of Medicine at Northwestern University, Chicago, IL.
Seattle Cancer Care Alliance, Seattle, WA.
JCO Oncol Pract. 2020 Dec;16(12):811-819. doi: 10.1200/OP.20.00431. Epub 2020 Sep 28.
Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing.
由于指南的扩大以及针对靶向治疗的选择，对前列腺癌（PCa）患者进行种系基因检测现在已成为常规建议。然而，由于需要检测的 PCa 患者数量增加，以及获得遗传咨询师的机会有限，将基因检测纳入肿瘤学和泌尿科临床工作流程仍然具有挑战性。这表明遗传服务在历史模型之外存在着迫切的需求。本文综述了 PCa 基因检测的现行指南、注意事项和挑战，并为遗传咨询和检测提供了实用指南，提出了解决方案以帮助解决提供者和患者潜在的障碍和挑战。随着遗传和基因组检测成为 PCa 治疗的重要组成部分，在临床中开发实施的标准化系统对于为 PCa 患者提供精准肿瘤学以及实现基因检测的全面范围和影响至关重要。
